Jason M Wiebelhaus, Kevin A Webster, Herbert Y Meltzer, Joseph H Porter
Index: Behav. Pharmacol. 22(5-6) , 458-67, (2011)
Full Text: HTML
It has been previously shown that cross-tolerance to the discriminative stimulus properties of clozapine can be demonstrated with the drug discrimination paradigm. This study examined the ability of N-desmethylclozapine and N-desmethylolanzapine (metabolites of the atypical antipsychotic drugs clozapine and olanzapine, respectively) to induce cross-tolerance to the discriminative stimulus effects of clozapine. After C57BL/6 mice were trained to reliably discriminate 2.5 mg/kg clozapine from vehicle, a clozapine generalization curve was generated. Next, training was suspended and the mice received a maintenance dosing regimen in which they were injected twice daily with 10 mg/kg N-desmethylclozapine for 10 days. Then a second clozapine generalization curve was generated. This was followed by a 10-day washout period during which the mice did not receive drug injections or discrimination training. Finally, a third clozapine generalization curve was generated. These same procedures were followed for N-desmethylolanzapine (10 mg/kg twice daily during maintenance dosing). Both N-desmethylclozapine and N-desmethylolanzapine produced significant rightward shifts in the clozapine generalization curve indicating cross-tolerance between N-desmethylclozapine and clozapine and between N-desmethylolanzapine and clozapine. After a washout period with no training or drug administration this cross-tolerance effect was lost for both metabolites. This cross-tolerance drug discrimination procedure demonstrated in-vivo similarities between these two metabolites and clozapine and suggests that common underlying pharmacological mechanisms were responsible for the cross-tolerance that was observed. These findings also demonstrated that this procedure may be useful for identifying drugs with therapeutic efficacy similar to the atypical antipsychotic clozapine under repeated dosing conditions.
| Structure | Name/CAS No. | Molecular Formula | Articles |
|---|---|---|---|
![]() |
N-Desmethyl Clobazam
CAS:22316-55-8 |
C15H11ClN2O2 |
|
Blood concentrations of clobazam and norclobazam in a lethal...
2010-11-01 [Leg. Med. (Tokyo.) 12(6) , 300-4, (2010)] |
|
Simultaneous determination of clobazam and its major metabol...
2005-09-05 [J. Chromatogr. B. Analyt. Technol. Biomed. Life Sci. 823(2) , 167-71, (2005)] |
|
A major influence of CYP2C19 genotype on the steady-state co...
2004-12-01 [Brain Dev. 26(8) , 530-4, (2004)] |
|
Analysis of clobazam and its active metabolite norclobazam i...
1996-11-01 [Scand. J. Clin. Lab. Invest. 56(7) , 609-14, (1996)] |
|
Eye rolling as a manifestation of clobazam toxicity in a chi...
2006-07-01 [Dev. Med. Child Neurol. 48(7) , 612-5, (2006)] |
Home | MSDS/SDS Database Search | Journals | Product Classification | Biologically Active Compounds | Selling Leads | About Us | Disclaimer
Copyright © 2024 ChemSrc All Rights Reserved
